Review
Biochemistry & Molecular Biology
Nora D. Volkow, Carlos Blanco
Summary: The current opioid epidemic in the US is one of the most severe public health crises in the country's history, and addressing it is challenging due to its rapidly changing nature and serious outcomes. Success in addressing the crisis will require advances in basic science, development of more acceptable and effective treatments, and implementation of public health approaches, including prevention. The progress made in addressing this crisis should also advance the science and treatment of other substance use disorders.
MOLECULAR PSYCHIATRY
(2021)
Article
Medicine, General & Internal
Tara Gomes, Tonya J. Campbell, Sophie A. Kitchen, Ria Garg, Nikki Bozinoff, Siyu Men, Mina Tadrous, Charlotte Munro, Tony Antoniou, Dan Werb, Jennifer Wyman
Summary: A retrospective cohort study in Ontario, Canada during the COVID-19 pandemic found that providing increased take-home doses of opioid agonist therapy was associated with lower risks of treatment interruption and discontinuation. The study did not show a significant increase in opioid-related overdoses over 6 months of follow-up.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2022)
Article
Public, Environmental & Occupational Health
Lisa M. Letourneau
Summary: Rural states and communities are facing significant challenges in addressing the ongoing opioid epidemic and implementing strategies for prevention and treatment tailored for their unique needs. Evidence-based approaches and tailored options are crucial for the success of combating this deadly epidemic in rural areas.
PREVENTIVE MEDICINE
(2021)
Article
Medicine, General & Internal
Julie M. Donohue, Marian P. Jarlenski, Joo Yeon Kim, Lu Tang, Katherine Ahrens, Lindsay Allen, Anna Austin, Andrew J. Barnes, Marguerite Burns, Chung-Chou H. Chang, Sarah Clark, Evan Cole, Dushka Crane, Peter Cunningham, David Idala, Stefanie Junker, Paul Lanier, Rachel Mauk, Mary Joan McDuffie, Shamis Mohamoud, Nathan Pauly, Logan Sheets, Jeffery Talbert, Kara Zivin, Adam J. Gordon, Susan Kennedy
Summary: The study found that the prevalence of medication use for the treatment of opioid use disorder among Medicaid enrollees in 11 states in the US increased from 2014 through 2018. Further research is needed to understand the situation in other states.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2021)
Article
Medicine, General & Internal
Janet M. Currie, Molly K. Schnell, Hannes Schwandt, Jonathan Zhang
Summary: The study shows that existing patients maintained access to opioid analgesics and buprenorphine for opioid use disorder during the COVID-19 pandemic. Prescriptions for opioid-naive patients briefly decreased and rebounded, while initiation of buprenorphine remained at a low rate through August 2020.
Article
Medicine, General & Internal
Elizabeth J. Austin, Jessica Chen, Elsa S. Briggs, Lori Ferro, Paul Barry, Ashley Heald, Joseph O. Merrill, Geoffrey M. Curran, Andrew J. Saxon, John C. Fortney, Anna D. Ratzliff, Emily C. Williams
Summary: This study explores the experiences and perspectives of multidisciplinary primary care (PC) teams in initiating or expanding medication for opioid use disorder (MOUD). The results suggest that PC teams face challenges in providing rapid access to care and engaging patients with MOUD, as well as maintaining clinician confidence. Attitudes towards MOUD expansion vary among PC teams. The study highlights the need for flexibility in appointment scheduling, effective patient engagement, and ongoing training to address evolving opioid-related clinical issues.
Article
Multidisciplinary Sciences
Dara M. Kusic, Jessica Heil, Stefan Zajic, Andrew Brangan, Oluseun Dairo, Stacey Heil, Gerald Feigin, Sherri Kacinko, Russell J. Buono, Thomas N. Ferraro, Rachel Rafeq, Rachel Haroz, Kaitlan Baston, Elliot Bodofsky, Michael Sabia, Matthew Salzman, Alissa Resch, Jozef Madzo, Laura B. Scheinfeldt, Jean-Pierre J. Issa, Jaroslav Jelinek
Summary: The United States is facing a long-standing opioid misuse epidemic, exacerbated by the COVID-19 pandemic and the rising use of powerful synthetic opioids like fentanyl. The Camden Opioid Research Initiative (CORI) aims to study this complex issue, finding that co-occurring substance use is common among opioid toxicity deaths, while medication-assisted treatment is infrequently observed. Efforts to address the opioid misuse epidemic must consider the complexities of co-occurring stimulant and other substance use, and reduce the barriers and stigma associated with seeking effective medication-assisted treatments.
Editorial Material
Health Care Sciences & Services
Parisa Mortaji, Dale Terasaki, Jaime Moo-Young
Summary: Opioid use disorder has impacted many lives in the US, with medications like buprenorphine shown to decrease mortality in patients. This case study of a 32-year-old woman undergoing multiple surgeries highlights the use of buprenorphine/naloxone, methadone, and a novel microdosing approach. The report aims to provide hospital-based providers with insights on managing peri-operative patients on medications for opioid use disorder.
JOURNAL OF GENERAL INTERNAL MEDICINE
(2021)
Article
Medicine, General & Internal
Michael L. L. Barnett, Ellen Meara, Terri Lewinson, Brianna Hardy, Deanna Chyn, Moraa Onsando, Haiden A. A. Huskamp, Ateev Mehrotra, Nancy E. E. Morden
Summary: An analysis of Medicare claims data from 2016-2019 revealed that white patients were more likely to receive medications for opioid use disorder (OUD) compared to black and Hispanic patients. Despite an increase in opioid overdose-related mortality among black individuals, racial and ethnic disparities in the use of OUD medications remained consistent and substantial over time.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Review
Pharmacology & Pharmacy
Michael Soyka
Summary: Methadone and buprenorphine are commonly used medications in opioid maintenance treatment, with no established algorithm for transitioning between them. Transfer is recommended for patients on low doses of methadone, but there are reports suggesting transition from higher doses may be possible. Various dosing strategies have been proposed to alleviate withdrawal symptoms and facilitate transfer.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Medicine, General & Internal
Madeline C. Frost, Lan Zhang, H. Myra Kim, Lewei (Allison) Lin
Summary: The study found that many patients accessed buprenorphine via telephone, and some were less likely to have any video visits. The results suggest that discontinuing or reducing telephone access may disrupt treatment for many patients, particularly groups with access disparities such as Black patients and those experiencing homelessness.
Article
Biochemistry & Molecular Biology
Wilson M. Compton, Rita J. Valentino, Robert L. DuPont
Summary: The U.S. opioid crisis is not limited to opioids, but also involves multiple substances. The overlap of different substances contributes to increased morbidity and mortality, and may have unique effects. Addressing the overlap between opioids and other substances is essential to maximize benefits in prevention, treatment, overdose reversal, public health surveillance, and research.
MOLECULAR PSYCHIATRY
(2021)
Article
Oncology
Katie Fitzgerald Jones, Dmitry Khodyakov, Robert Arnold, Hailey Bulls, Emily Dao, Jennifer Kapo, Diane Meier, Judith Paice, Jane Liebschutz, Christine Ritchie, Jessica Merlin
Summary: This qualitative study aims to establish consensus among palliative care and addiction specialists on the appropriateness of various opioid management strategies in individuals with advanced cancer-related pain and opioid misuse or OUD. The findings provide urgently needed guidance for clinicians and highlight critical research and policy gaps.
Review
Medical Informatics
Chrianna Bharat, Matthew Hickman, Sebastiano Barbieri, Louisa Degenhardt
Summary: The study highlights the need to accurately estimate overdose risk in individuals with opioid use disorder and explores the potential of predictive analytics and big data to reduce such risk. Collaboration among multiple agencies is necessary for improving treatment coverage and resources, as well as utilizing predictive modeling to predict diagnoses, treatment response, and provide targeted treatment recommendations for individuals with opioid use disorder.
LANCET DIGITAL HEALTH
(2021)
Article
Substance Abuse
Erin J. J. Stringfellow, Tse Yang Lim, Huiru Dong, Ziyuan Zhang, Mohammad S. S. Jalali
Summary: This study aimed to analyze the trends in buprenorphine receipt and the number of buprenorphine-waivered providers in the United States from 2003 to 2021, and examine whether the relationship between the two changed after capacity-building strategies were implemented in 2017. The findings showed that although there was an increase in the number of waivered providers, the growth in buprenorphine receipt by patients through retail pharmacies was not significant.
Article
Pharmacology & Pharmacy
Laney K. Jones, Vanessa Hayduk, Katrina M. Romagnoli, Alison Flango, Jami Marks, Jove Graham, Michael R. Gionfriddo
Summary: This study examines the implementation of a medication reconciliation educational program and its impact on clinic personnel knowledge and practice. The results show that the program was widely implemented and considered acceptable and appropriate, although adaptations were made to fit specific clinic needs.
JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION
(2022)
Review
Endocrinology & Metabolism
Laney K. Jones, Ross C. Brownson, Marc S. Williams
Summary: This review discusses implementation strategies for improving care of individuals with familial hypercholesteremia (FH) and compares them with expert-recommended change strategies. The study finds that only a few studies have used implementation science theories or frameworks, and only a couple of studies explicitly address health disparities or equity.
CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY
(2022)
Article
Cardiac & Cardiovascular Systems
Kristen M. Tecson, Aaron Y. Kluger, Andrea E. Cassidy-Bushrow, Bin Liu, Chad M. Coleman, Laney K. Jones, Celeena R. Jefferson, Jeffrey J. VanWormer, Peter A. McCullough
Summary: Clinical guidelines recommend statins for patients with atherosclerotic cardiovascular disease, but many remain untreated. This study found that statin use can reduce the risk of recurrent major adverse cardiovascular events, especially in the first 6 months after an ASCVD event.
AMERICAN JOURNAL OF CARDIOLOGY
(2022)
Article
Genetics & Heredity
Laney K. Jones, Natasha T. Strande, Evan M. Calvo, Jingheng Chen, Gabriela Rodriguez, Cara Z. McCormick, Miranda L. G. Hallquist, Juliann M. Savatt, Heather Rocha, Marc S. Williams, Amy C. Sturm, Adam H. Buchanan, Russell E. Glasgow, Christa L. Martin, Alanna Kulchak Rahm
Summary: This study used the RE-AIM framework to evaluate and report the outcomes of DNA-based population screening programs. The results showed that DNA screening identified at-risk individuals more comprehensively than clinical ascertainment based on phenotypes or personal/family history.
FRONTIERS IN GENETICS
(2022)
Article
Health Care Sciences & Services
Laney K. Jones, Marc S. Williams, Ilene G. Ladd, Dylan Cawley, Shuping Ge, Jing Hao, Dina Hassen, Yirui Hu, H. Lester Kirchner, Maria Kobylinski, Michael G. Lesko, Matthew C. Nelson, Alanna K. Rahm, David D. Rolston, Katrina M. Romagnoli, Tyler J. Schubert, Timothy C. Shuey, Amy C. Sturm, Samuel S. Gidding
Summary: The CARE-FH study aims to improve diagnostic evaluation rates for Familial Hypercholesterolemia (FH) through a collaborative approach. By using implementation science, the study transitions the initial evaluation for FH into primary care, in an attempt to identify individuals before the onset of atherosclerotic cardiovascular disease events.
JOURNAL OF PERSONALIZED MEDICINE
(2022)
Article
Pharmacology & Pharmacy
Scott J. Spencer, Laney K. Jones, Gregory F. Guzauskas, Jing Hao, Marc S. Williams, Josh F. Peterson, David L. Veenstra
Summary: Population-wide FH genomic screening is not cost-effective at current willingness to pay thresholds, but reducing test costs, screening at younger ages, or including FH within broader multiplex screening panels may improve clinical and economic value.
JOURNAL OF CLINICAL LIPIDOLOGY
(2022)
Article
Cardiac & Cardiovascular Systems
Laney K. Jones, Nan Chen, Dina A. Hassen, Megan N. Betts, Tracey Klinger, Dustin N. Hartzel, David L. Veenstra, Scott J. Spencer, Susan R. Snyder, Josh F. Peterson, Victoria Schlieder, Amy C. Sturm, Samuel S. Gidding, Marc S. Williams, Jing Hao
Summary: Limited information is available regarding clinician and participant behaviors after disclosure of genomic risk variants for familial hypercholesterolemia (FH) from a population genomic screening program. Nonprescribing and nonadherence to lipid-lowering therapy remained high after disclosure of an FH risk variant, but lipid levels decreased when clinicians intensified medication regimens and participants adhered to medications.
CIRCULATION-GENOMIC AND PRECISION MEDICINE
(2022)
Article
Health Care Sciences & Services
Anna Baker, Kasia Tolwinski, Jamie Atondo, F. Daniel Davis, Jessica Goehringer, Laney K. Jones, Cassandra J. Pisieczko, Amy C. Sturm, Janet L. Williams, Marc S. Williams, Alanna Kulchak Rahm, Adam H. Buchanan
Summary: Understanding individuals' experiences receiving genetic results is crucial for clinical utility and population health improvement. Through qualitative interviews, this study explored the response of individuals who received clinically actionable genetic results. The findings revealed that participants were satisfied with the disclosure process, initially had a range of psychological reactions to the results, and took actions and communicated the results with close relatives.
JOURNAL OF PERSONALIZED MEDICINE
(2022)
Article
Pharmacology & Pharmacy
Anandita Agarwala, Elena Deych, Laney K. Jones, Amy C. Sturm, Karen Aspry, Zahid Ahmad, Christie M. Ballantyne, Anne C. Goldberg
Summary: This study retrospectively examined the burden and risk factors of premature ASCVD in men and women with FH. The results showed a high prevalence of premature ASCVD in both genders, and significant differences were observed in predictive factors and lipid treatment outcomes for women with premature ASCVD.
JOURNAL OF CLINICAL LIPIDOLOGY
(2023)
Review
Pharmacology & Pharmacy
Tyler J. Schubert, Katarina Clegg, Dean Karalis, Nihar R. Desai, Joel C. Marrs, Catherine McNeal, Guy L. Mintz, Katrina M. Romagnoli, Laney K. Jones
Summary: Telehealth services have had positive to neutral impacts on lipid management, with facilitators including easier implementation of multidisciplinary approaches and patient-centered programs. However, barriers such as technological limitations, cost, patient non-adherence, and difficulty standardizing care need to be addressed. More research is needed to assess the potential of telehealth as a sustainable tool for lipid management.
JOURNAL OF CLINICAL LIPIDOLOGY
(2023)
Article
Cardiac & Cardiovascular Systems
Gerald F. Watts, Samuel S. Gidding, Robert A. Hegele, Frederick J. Raal, Amy C. Sturm, Laney K. Jones, Mitchell N. Sarkies, Khalid Al-Rasadi, Dirk J. Blom, Magdalena Daccord, Sarah D. de Ferranti, Emanuela Folco, Peter Libby, Pedro Mata, Hapizah M. Nawawi, Uma Ramaswami, Kausik K. Ray, Claudia Stefanutti, Shizuya Yamashita, Jing Pang, Gilbert R. Thompson, Raul D. Santos
Summary: Familial hypercholesterolaemia (FH) is a preventable cause of premature coronary artery disease and death. This guidance article from the International Atherosclerosis Society provides a comprehensive overview of FH care that includes recommendations on the detection and management of patients with FH, as well as strategies to maximize implementation.
NATURE REVIEWS CARDIOLOGY
(2023)
Article
Hematology
Alexander S. F. Berry, Laney K. Jones, Eric J. Sijbrands, Samuel S. Gidding, Matthew T. Oetjens
Summary: This study found that genetic subtyping based on monogenic familial hypercholesterolemia and Lp(a) provides better stratification of 10-year incident CAD risk than LDL-C-based stratification in individuals with severe hypercholesterolemia.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
(2023)
Review
Peripheral Vascular Disease
Mary Katherine Cheeley, Katarina Clegg, Connor Lockridge, Tyler J. J. Schubert, Laney K. K. Jones
Summary: The purpose of this review is to examine recent definitions, considerations, and treatment algorithms for statin intolerance, particularly statin-associated muscle symptoms (SAMS). Multiple organizations worldwide have provided guidance documents to help clinicians manage statin intolerance. These documents emphasize the importance of statin therapy for reducing atherosclerotic cardiovascular disease (ASCVD) and the need to assess and rechallenge patients who cannot tolerate statins.
CURRENT ATHEROSCLEROSIS REPORTS
(2023)
Article
Cardiac & Cardiovascular Systems
Laney K. Jones, Nicole Walters, Andrew Brangan, Catherine D. Ahmed, Katherine A. Wilemon, Gemme Campbell-Salome, Alanna K. Rahm, Samuel S. Gidding, Amy C. Sturm
Summary: The study aimed to explore the alignment of perspectives from individuals and families with FH to the recommendations of the FH Global Call to Action. The results showed that participants were most concerned about family-based care, screening, testing and diagnosis, and treatment. Improvements in screening and family-based care are crucial to addressing the concerns of patients and public health.
AMERICAN JOURNAL OF PREVENTIVE CARDIOLOGY
(2022)
Article
Hematology
Benjamin Andrick, Lorraine Tusing, Laney K. Jones, Yirui Hu, Rachel Sneidman, Christina Gregor, Soumit Basu, Joseph P. Lynch, Joseph Vadakara
Summary: This study describes the implementation of a hematopoietic cellular therapy (HCT) pharmacist at a transplantation center and evaluates the program using the RE-AIM framework. The results demonstrate that the introduction of an HCT pharmacist positively impacts patient care, and the pharmacist's services are gradually adopted and expanded.
TRANSPLANTATION AND CELLULAR THERAPY
(2022)